If you fancy a flutter, GERN could be a great place to start, option traders are expecting a move of up to $40 % on Monday as a result of the outcome from the Phase Data results been released tomorrow at the HOC conference. Like any Bio stock it is risky to trade but can be very rewarding,so play carefully.
AVERAGE ANALYSTS PRICE TARGET $3.5
AVERAGE ANALYSTS...
Geron Group has been on a explosive move forward in 2019 and like many Pharmaceutical companies it is moving on very little publicly released news. We have a alert on the stock for a break of $2.40 where it meets resistance and the 200ma with a major gap above.
GERN dropped very badly in premarket today because of some bad news involving Johnson & Johnson's (NYSE:JNJ) Janssen unit. I was curious to see if there was any insider trading in the days before the news was released. I found out there were two transactions, both of the director and the secretary sold a total of $7 million dollars in late August - middle...
This stock has been in our watchlist for a few weeks now. From the last pullback we had last week and a tested level on the demand zone, we are now more convince with this as one with potential growth.
With JNJ as a backing, let's hope this happen.
Possible Double Bottom at $5.10
Stock looks like its ready to run and run fast
If $5.10 can represent the low going forward, we break above multi-year resistance of $6.50 and hold;
might get a double here!
Time will tell.
... for a 3.22 debit.
Max Profit: $78/contract
Max Loss/Buying Power Effect: $322 per contract
Break Even/Cost Basis: 3.22/share
Notes: A speculative shot on a high implied volatility biotech underlying ... .
there has been so much good news about this company it must still be breaking out.. high volume above all moving averages and the macd and momentum indicators all say it's good
since the macd is about to cross over again, it wouldnt surprise me if monday morning this should drop but then catch itself, but I am still not sure..
i got a Sales Pitch call "Belford Style" which resembled basically the Wolf of Wallstreet Sales and the "Boileroom Closer" in a single phone conversation.
the call happend while i was trading the markets live, and happend to record a few bits out of it.
here is a small cutout of it on Youtube: youtu.be
so this Idea serves as a reminder of...
I took a position last Thursday, had a 13% profit by Friday, then the stock fell apart. Love to hear comments on what is going on. I had my first target set to sell at 5.17. Thank you
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. Janssen is engaged in the development of Imetelstat with two clinical trials, such as a Phase II trial in myelofibrosis (MF), referred to as IMbark, and a Phase II/III trial in myelodysplastic syndromes (MDS) referred to as IMerge. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the RNA template of telomerase, thereby directly inhibiting telomerase activity.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
GERN
